Saratov JOURNAL of Medical and Scientific Research

The frst results of combined treatment of central serous chorioretinopathy using subthreshold micropulse laser exposure with 577 nm wavelength and injections of platelet autoplasma


Aim: to compare the efects of a combination of subthreshold micropulse laser irradiation (SMPLI) with injections of autologous platelet plasma (PP) in the region of the pterygopal fossa on the afected side with the efect of SMPLI in central serous chorioretinopathy (CSСR). Material and Methods. This study was conducted on 60 patients (60 eyes) with CSCR. Patients were divided into 2 groups: in the comparison group patients received treatment only with SMPLI with a wavelength of 577 nm. In the experimental group patients received SMPLI with TP injections. TP was started after 72 hours, with 3 injections into the area of pterygopalatine fossa in the afected eye, with an interval between injections of 72 hours. Ophthalmologic examination, OCT and fuorescent angiography were carried out before treatment and 1, 3, 6 and 12 months after treatment, and ELISA assessment of IL-4, — 6 and -17A levels in lacrimal fuid was performed. Results. In the experimental group, where SMPLI+TP were performed, visual acuity has signifcantly improved, thickness of central section of macula was noted to have been decreased, and photosensitivity of central zone of retina signifcantly improved when compared to the SMPLI group. In the SMPLI+TP group the levels of IL-4, IL-6 and IL-17A in tear fuid increased. SMPLI was performed using Supra 577 nm laser device (Quantel Medical, France) over the entire area of macular edema. Conclusion. SMPLI+PRP treatment in patients with acute CSCR is efective for restoration of visual function.

1 Chen G, Tzekov R, Li W, et al. Subfoveal choroidal thickness in central serous chorioretinopathy: A meta-analysis. PLoS ONE 2017 DOI: 10.1371 / journal. pone. 169152
2 Daruich A, Matet A, Diran A, et al. Central serous chorioretinopathy: Recent fndings and new physiopathology hypothesis. Prog Retin Eye Res 2015; (48): 82–118
3 Lai WY, Tseng CL, Wu TT, et al. Correlation between baseline retinal microstructures in spectral-domain optic coherence tomography and need for early intervention in central serous chorioretinopathy. BMJ Open Ophth 2017 DOI: 10.1136 / bmjophth-2016–0000548 4 Liew G, Quin G, Gillies M, et al. Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol 2013; (41): 201–14. 5 Moschos M, Brouzas D, Koutsandrea C, et al. Assessment of central serous chorioretinopathy by optical coherence tomography and multifocal electroretinography. Ophthalmologica 2007; (221): 292–8. 6 Nicholson B, Noble J, Forooghian F, et al. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol 2013; 58 (2): 103–26. 7 Sugiura A, Fujino R, Takemiya N, et al. The association between visual function and retinal structure in chronic central serous chorioretinopathy. Scientifc Reports 2017 DOI: 10.1038 / s41598-017-16339-9. 8 Yannuzzi LA. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol 2010; (149): 361–3. 9 Yu L, Shao Y, Chai Y, et al. Retinal microvasculature alteration in central serous chorioretinopathy. Molecular Medicine Reports 2018; (17): 2335–40. 10 Kitzmann AS, Pulido JS, Diehl NN, et al. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology 2008; (115): 169–73. 11 Wang M, Munch IC, Hasler PW, et al. Central serous chorioretinopathy. Acta Ophthalmologica 2008; (86): 126– 45 12 Dolar-Szczasny J, Swięch-Zubilewicz A, Mackiewicz J. Macular integrity assessment and fxation analysis in chronic centrals chorioretinopathy. J Ophthalmol 2018 DOI: 10.1155 / 2018 / 9479848 13 Imamura Y, Fujiwara T, Margolis R, et al. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 2009; (29): 1469–73. 14 Kim YJ, Lee YG, Lee DW, et al. Selective retina Therapy with real-time feedback-controlled fosimetry for freating acute idiopathic central serous chorioretinopathy in Korean patients. J Ophthalmol 2018 DOI: 10.1155 / 2018 / 6027871 15 Nikkhah H, Karimi S, Ahmadieh H, et al. Intravitreal injection of antivascular endothelial growth factor agents for ocular vascular diseases: Clinical practice guideline. J Ophthalmic Vis Res 2018; (13): 158–69. 16 Semeraro F, Russo A, Delcassi L, et al. Recurrent central serous chorioretinopathy after peripheral retinal laser photocoagulation: a case report. Eur J Ophthalmol 2013; 23 (2): 258–61. 17 Kang S, Park YG, Kim JR, et al. Selective retina therapy in patients with chronic central serous chorioretinopathy: a pilot study. Medicine 2016 DOI: 10.1097 / MD. 2524 18 Mehta PH, Meyerle C, Sivaprasad S, et al. Preferred practice pattern in central serous chorioretinopathy. Br J Ophthalmol 2017; (101): 587–90. 19 Wood EH, Karth PA, Sanislo SR, et al. Nondamaging retinal laser therapy for treatment of central serous chorioretinopathy: What is the evidence? Retina 2017; (37): 1021–33. 20 Scholz P, Altay L, Fauser S. Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy. Eye (Lond) 2016; 30 (10): 1371–7. 21 Alio JL, Rodriguez AE, Ferreira-Oliveira R, et al. Treatment of Dry Eye Disease with Autologous Platelet-Rich Plasma: A Prospective, Interventional, Non-Randomized Study. Ophthalmol Ther 2017; (6): 285–93. 22 Garcia-Conca V, Abad-Collado M, Hueso-Abancens JR, et al. Efcacy and safety of treatment of hyposecretory dry eye with platelet-rich plasma. Acta Ophthalmol 2018 DOI: 10.1111 / aos. 13907 23 Kim KM, Shin YT, Kim HK. Efect of autologous platelet-rich plasma on persistent corneal epithelial defect after infectious keratitis. Jpn J Ophthalmol 2012; (56): 544–50. 24 Marquez-de-Aracena R, Montero-de-Espinosa I, Munoz M, et al. Subconjunctival application of plasma platelet concentrate in the treatment of ocular burns: Preliminary results. Arch Soc Esp Oftalmol 2007; (82): 475–81. 25 Pezzotta S, Del Fante C, Scudeller L, et al. Autologous platelet lysate for treatment of refractory ocular GVHD. Bone Marrow Transplant 2012; (47): 1558–63. 26 Ghodasra DH, Fante R, Gardner TW, et al. Safety and feasibility of quantitative multiplexed cytokine analysis from ofce-based vitreous aspiration. Invest Ophthalmol Vis Sci 2016; (57): 3017–23. 27 Jung SH, Kim KA, Sohn SW, et al. Cytokine levels of the aqueous humour in central serous chorioretinopathy. Clin Exp Optom 2014; (97): 264–9. 28 Shin MC, Lim JW. Concentration of cytokines in the aqueous humor of patients with central serous chorioretinopathy. Retina 2011; (31): 1937–43. 29 Lim JW, Kim MU, Shin MC. Aqueous humor and plasma levels of vascular endothelial growth factor and interleukin-8 in patients with central serous chorioretinopathy. Retina 2010; (30): 1465–71. 30 Terao N, Koizumi H, Kojima K, et al. Association of Upregulated Angiogenic Cytokines with Choroidal Abnormalities in Chronic Central Serous Chorioretinopathy. Invest Ophthalmol Vis Sci 2018; 59 (15): 5924–31.

2019_02-1_539-543.pdf280.13 KB

No votes yet